Tapahtumakalenteri (vanha)

toukokuu 03

Kliinisen mikrobiologian perjantaisarja

Veripalvelun mikrobiologia

Riikka Lehtisalo, infektioista vastaava lääkäri, Veripalvelu 


 


Aloitusaika: 03.05.2024 10:00
Lopetusaika: 03.05.2024 11:00
Kesto: 1 hour
Sijainti: remotely
Tyyppi: Seminar
Organisaatio: HUS
Yhteyshenkilö: kira.ranta@hus.fi
toukokuu 03

Dissertation: Laura Auvinen-Lintunen

Laura Auvinen-LintunenUniversity of Helsinki, Faculty of Medicine, Doctoral Programme in Cognition, Learning, Instruction and Communicatio, Finnish Institute for Health and Welfare, Mental Health, Public Health and Welfare Helsinki University Central Hospital, Department of Psychiatry
Mental imagery deficits in young violent offenders and individuals with recent-onset psychosis

Opponent: professoriJuha Holma, University of Jyväskylä


Aloitusaika: 03.05.2024 12:00
Lopetusaika: 03.05.2024 14:00
Kesto: 2 hours
Sijainti: Metsätalo, sali 1, Unioninkatu 40
Tyyppi: Dissertation
Organisaatio: UH, Faculty of Medicine
Yhteyshenkilö: laura.auvinen-lintunen@helsinki.fi
toukokuu 08

FICAN webinar: prof Olli Lohi

Precision Therapy for Childhood Leukemia: Improving Outcomes and Reducing Toxicities
Speaker: prof. Olli Lohi, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital
FICAN webinars are jointly organized by regional cancer centers. This webinar is organized by FICAN Mid- Sisä-Suomen syöpäkeskus.
The seminar will be held online (Microsoft Teams) and is open to everyone interested in cancer research. Teams link can be found below.

Abstract: Childhood acute lymphoblastic leukemia (ALL), the most common cancer among children, has traditionally been managed with chemotherapy regimens. While these treatments are effective, they often lead to significant toxicities and long-term side effects for survivors. The implementation of response-based risk grouping has been crucial in customizing therapies, thereby significantly enhancing outcomes and reducing treatment-related toxicities. The introduction of modern sequencing technologies has unveiled the complexity of the disease by identifying numerous genetically distinct subtypes, each with unique behaviors and responses to treatment. This shift towards personalized medicine is underscored by the exploration of immunotherapies and novel targeted agents for cases that relapse or show poor response, representing a considerable departure from conventional chemotherapy methods.

Our recent discovery involves the application of the general tyrosine kinase inhibitor dasatinib as a targeted treatment for both T-cell and B-cell ALL. In particular, the effectiveness of a combination therapy that included dasatinib and temsirolimus for T-ALL was shown in patient samples and preclinical animal models. Additionally, the sequential treatment of B-ALL with an inhibitor of Wee1, a cell cycle regulator, and dasatinib was effective in eliminating an escape pathway for residual leukemic cells. Furthermore, in collaboration with European partners, we have begun to delineate the genetic landscape of slow responding leukemias within the second common subtype of ALL, expected to have a favorable outcome.

The importance of international collaboration is critical in hastening the development of novel treatments for childhood leukemias. The advent of immunotherapies as a frontline therapy modality represents the next frontier, with high hopes for achieving greater efficacy and reduced harm simultaneously.

Selected publications:

Zapilko V, Moisio S, Parikka M, Heinäniemi M, Lohi O. Generation of a Zebrafish Knock-In Model Recapitulating Childhood ETV6::RUNX1-Positive B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2023 Dec 13;15(24):5821. doi: 10.3390/cancers15245821. PMID: 38136366; PMCID:
PMC10871125.

Krali O, Marincevic-Zuniga Y, Arvidsson G, Enblad AP, Lundmark A, Sayyab S, Zachariadis V, Heinäniemi M, Suhonen J, Oksa L, Vepsäläinen K, Öfverholm I, Barbany G, Nordgren A, Lilljebjörn H, Fioretos T, Madsen HO, Marquart HV, Flaegstad T, Forestier E, Jónsson ÓG, Kanerva J, Lohi O, Norén-Nyström U, Schmiegelow K, Harila A, Heyman M, Lönnerholm G, Syvänen AC, Nordlund J. Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia. NPJ Precis Oncol. 2023 Dec 8;7(1):131. doi: 10.1038/s41698-023-00479-5. PMID: 38066241; PMCID: PMC10709574.

Laukkanen S, Veloso A, Yan C, Oksa L, Alpert EJ, Do D, Hyvärinen N, McCarthy K, Adhikari A, Yang Q, Iyer S, Garcia SP, Pello A, Ruokoranta T, Moisio S, Adhikari S, Yoder JA, Gallagher K, Whelton L, Allen JR, Jin AH, Loontiens S, Heinäniemi M, Kelliher M, Heckman CA, Lohi O, Langenau DM. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022 Oct 27;140(17):1891-1906. doi: 10.1182/blood.2021015106. PMID: 35544598; PMCID: PMC10082361.

Mehtonen J, Teppo S, Lahnalampi M, Kokko A, Kaukonen R, Oksa L, Bouvy-Liivrand M, Malyukova A, Mäkinen A, Laukkanen S, Mäkinen PI, Rounioja S, Ruusuvuori P, Sangfelt O, Lund R, Lönnberg T, Lohi O, Heinäniemi M. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome Med. 2020 Nov 20;12(1):99. doi: 10.1186/s13073-020-00799-2. PMID: 33218352; PMCID: PMC7679990.


Aloitusaika: 08.05.2024 15:00
Lopetusaika: 08.05.2024 16:00
Kesto:
Sijainti: remotely
Tyyppi: Webinar
Organisaatio: Finnish Cancer Center (FICAN)
Yhteyshenkilö: anne.kairenius@hus.fi